Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a ...

Teva files an NDA seeking FDA approval for its once-monthly olanzapine LAI for the treatment of adults with schizophrenia.

Boehringer Ingelheim plans to submit its app to treat under-addressed symptoms of schizophrenia for FDA clearance.

The FDA has approved a new oral drug for use in adults with schizophrenia. Photo by toubibe/Pixabay. Sept. 26 (UPI) --The U.S. Food and Drug Administration has approved a new drug for adults with ...

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population 2 Olanzapine LAI is designed ...

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb, combines ...

In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...

In the months after 24-year-old D.J. was diagnosed with schizophrenia, he searched online for answers to questions that felt urgent and existential. Does it get really bad over time? Will I be able to ...

Recent clinical research indicates that semaglutide may effectively reverse weight gain and blood sugar issues caused by ...

Sept. 26 (UPI) --The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia, the FDA announced Thursday. The drug, generically called Cobenfy, is the first oral ...

A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Md. automation The U.S. Food and Drug Administration (FDA) on Thursday approved the first ...